×

Food and Staples Retailing Drug Retail

  • Accountant for Martin Shkreli's drug company had 'WTF' moment when reviewing firm's 'chaotic' books

    "It was very difficult" to get information about Retrophin's financial statements from Martin Shkreli, an accountant said.

  • A Novartis lab

    Novartis' cancer drug may be the first gene therapy approved in the U.S., after being backed by a federal advisory panel.

  • Virus

    Gonorrhea is becoming harder to treat due to antibiotic resistance, health professionals at the World Health Organization have warned.

  • Pharmacy benefits manager Appro-Rx on bringing clarity to drug prices

    Kyle Fields, Appro-Rx CEO, discusses how his company is working on transparency in drug pricing as a pharmacy benefits manager.

  • By Siddharth Cavale and Diane Bartz. June 29- Drugstore chain Walgreens Boots Alliance Inc scrapped its deal to buy Rite Aid Corp after failing to win antitrust approval, but said it would instead buy nearly half of the smaller rival's U.S. stores for $5.18 billion. Rite Aid's shares plunged about 30 percent to $2.77, while Walgreens shares were flat at $76.91...

  • June 29- Drugstore chain Walgreens Boots Alliance Inc scrapped its deal to buy Rite Aid Corp after failing to win antitrust approval, but said it would instead buy nearly half of the smaller rival's U.S. stores for $5.18 billion. Rite Aid's shares plunged 25 percent to $2.93, while Walgreens shares were up slightly at $77.33. They decided to end the deal after the...

  • WBA shares rise 5 pct, RAD and Fred's shares fall 20 pct. Rite Aid's shares plunged 22 percent to $3.07, while Walgreens shares were up 5 percent at $81.02. The previous $9.5 billion deal, announced in October 2015, faced tough antitrust scrutiny as regulators deliberated over the effects of a merger between the No. 1 and No. 3 drug store chains in the United States...

  • Failed Walgreen's merger sends Rite Aid plunging ahead of market open

    The "Squawk on the Street" crew discusses Walgreen's failed deal with Rite Aid and the company's quarterly results.

  • the United States would stymie competition. 1/ 8 http://reut.rs/2kFULFa. Walgreens also reported better-than-expected profit and sales for the third quarter, helped by a rise in prescription volumes in its pharmacy business in the United States. The company also authorized a $5 billion buyback program and raised the bottom end of its full-year profit...

  • A delivery to a Walgreens location in New York City.

    Walgreens Boots Alliance canceled its previous merger deal with Rite Aid and replaced it with a new agreement, which also impacts Fred's.

  • June 29- Drugstore chain Walgreens Boots Alliance Inc terminated its agreement to buy smaller rival Rite Aid Corp after struggling to win antitrust approval, and said it would instead buy 2,186 Rite Aid stores and assets for $5.18 billion in cash. Walgreens shares were up 1.7 percent at $78.49, while Rite Aid's shares were down 3 percent at $3.68.

  • June 29- Drugstore chain Walgreens Boots Alliance Inc said on Thursday it terminated its agreement to buy Rite Aid Corp, and would instead buy 2,186 Rite Aid stores and some distribution centers for $5.18 billion in cash.

  • Allergan CEO on the battle over drug pricing

    CNBC's Meg Tirrell talks to Brent Saunders, Allergan CEO, about an executive order on possibly lowering drug prices live from the Heartland Health Summit.

  • SANTIAGO, May 10- Pharmacies in Chile's capital Santiago will start selling cannabis-based medicines this week, the first time such treatments have been offered by drug stores in Latin America, the companies behind the launch said on Wednesday. Chile legalized the use of medical marijuana in 2015 and is among a number of Latin American countries gradually...

  • *Q1 adj EPS $1.17 vs est $1.10. May 2- CVS Health Corp reported a bigger-than-expected quarterly profit as higher margins in its pharmacy business helped offset the loss of major contracts last year. Same-store prescription volumes fell 460 basis points in the first quarter due to the loss of contracts to fill prescriptions for Tricare, a U.S. Department of...

  • Same-store sales at the front-end of stores, where the company sells beauty products, snacks and over-the-counter drugs, also fell 4.9 percent in the first quarter ended March 31. Net income attributable to CVS fell to $952 million, or 92 cents per share, in the first quarter ended March 31, from $1.15 billion, or $1.04 per share, a year earlier. Interest expense fell...

  • May 2- Drugstore chain and pharmacy benefits manager CVS Health Corp reported a 17 percent drop in quarterly profit, as it filled fewer prescriptions at its pharmacies and lower traffic hurt sales at the front-end of its stores. Net income attributable to CVS fell to $952 million, or 92 cents per share, in the first quarter ended March 31, from $1.15 billion, or $1.04...

  • What to expect from biotech

    CNBC's Meg Tirrell discusses what healthcare investors should expect from the biotech sector. With the "Fast Money" traders.

  • President Donald Trump meets with representatives from PhRMA, the Pharmaceutical Research and Manufacturers of America, in the Roosevelt Room of the White House on Jan. 31, 2017, in Washington, DC.

    Discussing who is to blame for higher drug pricing with Mark Merritt, PCMA CEO; Stephen Ubl, Pharmaceutical Research and Manufacturers of America (PhRMA) president and ceo; and CNBC's Meg Tirrell.

  • April 19- Canadian grocery and pharmacy retailer Loblaw Cos Ltd said on Wednesday it would sell its gas station business to asset manager Brookfield Business Partners LP for about C $540 million.